APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antibody Therapeutics and Blood Antibody Therapeutics

Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.

Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.

Selected research

Market Outlook & Growth Opportunities

Global Antibody Therapeutics and Blood Antibody Therapeutics Market Outlook and Growth Opportunities 2026

Report ID 173893550427 December 2025198 pages

Choose your research edition.

Industry ResearchAntibody Therapeutics and Blood Antibody Therapeutics Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody Therapeutics and Blood Antibody Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Antibody Therapeutics and Blood Antibody Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody Therapeutics and Blood Antibody Therapeutics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody Therapeutics and Blood Antibody Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.

Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.

The industry's leading producers are Roche, Abbvie and J & J, with revenues of 15.61%, 12.10% and 10.05% in 2019.

Read the full market overview

This report provides an overview of the global Antibody Therapeutics and Blood Antibody Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody Therapeutics and Blood Antibody Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody Therapeutics and Blood Antibody Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antibody Therapeutics and Blood Antibody Therapeutics market.

Antibody Therapeutics and Blood Antibody Therapeutics Segment by Company

Roche

Abbvie

Johnson & Johnson

Bristol-Myers Squibb

Novartis

Merck

Alexion Pharmaceuticals

Takeda

Amgen

Biogen

UCB

Eli Lilly and Company

AstraZeneca

Antibody Therapeutics and Blood Antibody Therapeutics Segment by Type

IgG1

IgG4

Others

Antibody Therapeutics and Blood Antibody Therapeutics Segment by Application

Autoimmune

Tumor

Others

Antibody Therapeutics and Blood Antibody Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antibody Therapeutics and Blood Antibody Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antibody Therapeutics and Blood Antibody Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Antibody Therapeutics and Blood Antibody Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antibody Therapeutics and Blood Antibody Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody Therapeutics and Blood Antibody Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody Therapeutics and Blood Antibody Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Therapeutics and Blood Antibody Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody Therapeutics and Blood Antibody Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Therapeutics and Blood Antibody Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody Therapeutics and Blood Antibody Therapeutics industry.

Chapter 3: Detailed analysis of Antibody Therapeutics and Blood Antibody Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antibody Therapeutics and Blood Antibody Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antibody Therapeutics and Blood Antibody Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody Therapeutics and Blood Antibody Therapeutics Industry Trends Table 2. Antibody Therapeutics and Blood Antibody Therapeutics Industry Drivers Table 3. Antibody Therapeutics and Blood Antibody Therapeutics Industry Opportunities and Challenges Table 4. Antibody Therapeutics and Blood Antibody Therapeutics Industry Restraints Table 5. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Antibody Therapeutics and Blood Antibody Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antibody Therapeutics and Blood Antibody Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Antibody Therapeutics and Blood Antibody Therapeutics Company, Product Type & Application Table 10. Global Antibody Therapeutics and Blood Antibody Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antibody Therapeutics and Blood Antibody Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of IgG1 Table 15. Significant Companies of IgG4 Table 16. Significant Companies of Others Table 17. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Autoimmune Table 23. Significant Companies of Tumor Table 24. Significant Companies of Others Table 25. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. Roche Company Information Table 41. Roche Business Overview Table 42. Roche Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Roche Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 44. Roche Recent Development Table 45. Abbvie Company Information Table 46. Abbvie Business Overview Table 47. Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 49. Abbvie Recent Development Table 50. Johnson & Johnson Company Information Table 51. Johnson & Johnson Business Overview Table 52. Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 54. Johnson & Johnson Recent Development Table 55. Bristol-Myers Squibb Company Information Table 56. Bristol-Myers Squibb Business Overview Table 57. Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 59. Bristol-Myers Squibb Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Novartis Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 64. Novartis Recent Development Table 65. Merck Company Information Table 66. Merck Business Overview Table 67. Merck Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Merck Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 69. Merck Recent Development Table 70. Alexion Pharmaceuticals Company Information Table 71. Alexion Pharmaceuticals Business Overview Table 72. Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 74. Alexion Pharmaceuticals Recent Development Table 75. Takeda Company Information Table 76. Takeda Business Overview Table 77. Takeda Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Takeda Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 79. Takeda Recent Development Table 80. Amgen Company Information Table 81. Amgen Business Overview Table 82. Amgen Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Amgen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 84. Amgen Recent Development Table 85. Biogen Company Information Table 86. Biogen Business Overview Table 87. Biogen Antibody Therapeutics and Blood Antibody Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Biogen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 89. Biogen Recent Development Table 90. UCB Company Information Table 91. UCB Business Overview Table 92. UCB Antibody Therapeutics and Blood Antibody Therapeutics Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 93. UCB Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 94. UCB Recent Development Table 95. Eli Lilly and Company Company Information Table 96. Eli Lilly and Company Business Overview Table 97. Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 98. Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 99. Eli Lilly and Company Recent Development Table 100. AstraZeneca Company Information Table 101. AstraZeneca Business Overview Table 102. AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 103. AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio Table 104. AstraZeneca Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Antibody Therapeutics and Blood Antibody Therapeutics Product Image Figure 2. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibody Therapeutics and Blood Antibody Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. IgG1 Image Figure 8. IgG4 Image Figure 9. Others Image Figure 10. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Autoimmune Image Figure 14. Tumor Image Figure 15. Others Image Figure 16. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • IgG1
  • IgG4
  • Others
Applications
  • Autoimmune
  • Tumor
  • Others
Companies covered
  • Roche
  • Abbvie
  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Novartis
  • Merck
  • Alexion Pharmaceuticals
  • Takeda
  • Amgen
  • Biogen
  • UCB
  • Eli Lilly and Company
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antibody Therapeutics and Blood Antibody Therapeutics Market Dynamics
  1. 2.1 Antibody Therapeutics and Blood Antibody Therapeutics Industry Trends
  2. 2.2 Antibody Therapeutics and Blood Antibody Therapeutics Industry Drivers
  3. 2.3 Antibody Therapeutics and Blood Antibody Therapeutics Industry Opportunities and Challenges
  4. 2.4 Antibody Therapeutics and Blood Antibody Therapeutics Industry Restraints
3 Antibody Therapeutics and Blood Antibody Therapeutics Market by Company
  1. 3.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Antibody Therapeutics and Blood Antibody Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Antibody Therapeutics and Blood Antibody Therapeutics Company Product Type and Application
  6. 3.6 Global Antibody Therapeutics and Blood Antibody Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antibody Therapeutics and Blood Antibody Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antibody Therapeutics and Blood Antibody Therapeutics Market by Type
  1. 4.1 Antibody Therapeutics and Blood Antibody Therapeutics Type Introduction
  2. 4.1.1 IgG1
  3. 4.1.2 IgG4
  4. 4.1.3 Others
  5. 4.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Type
  6. 4.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type (2021-2032)
5 Antibody Therapeutics and Blood Antibody Therapeutics Market by Application
  1. 5.1 Antibody Therapeutics and Blood Antibody Therapeutics Application Introduction
  2. 5.1.1 Autoimmune
  3. 5.1.2 Tumor
  4. 5.1.3 Others
  5. 5.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Application
  6. 5.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application (2021-2032)
6 Antibody Therapeutics and Blood Antibody Therapeutics Regional Value Analysis
  1. 6.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Antibody Therapeutics and Blood Antibody Therapeutics Country-level Value Analysis
  1. 7.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antibody Therapeutics and Blood Antibody Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Abbvie
  8. 8.2.1 Abbvie Company Information
  9. 8.2.2 Abbvie Business Overview
  10. 8.2.3 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  12. 8.2.5 Abbvie Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Alexion Pharmaceuticals
  38. 8.7.1 Alexion Pharmaceuticals Company Information
  39. 8.7.2 Alexion Pharmaceuticals Business Overview
  40. 8.7.3 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  42. 8.7.5 Alexion Pharmaceuticals Recent Developments
  43. 8.8 Takeda
  44. 8.8.1 Takeda Company Information
  45. 8.8.2 Takeda Business Overview
  46. 8.8.3 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  48. 8.8.5 Takeda Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 UCB
  62. 8.11.1 UCB Company Information
  63. 8.11.2 UCB Business Overview
  64. 8.11.3 UCB Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 UCB Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  66. 8.11.5 UCB Recent Developments
  67. 8.12 Eli Lilly and Company
  68. 8.12.1 Eli Lilly and Company Company Information
  69. 8.12.2 Eli Lilly and Company Business Overview
  70. 8.12.3 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  72. 8.12.5 Eli Lilly and Company Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst